Case: Patents/Anticipation & Obviousness (P.T.A.B.)

The Patent Trial and Appeal Board held that challenged claims of Tecan Genomics Inc.'s patent that provides methods, compositions, and kits for targeted nucleic acid sequence enrichment in a nucleic acid sample and for high efficiency nucleic acid library generation for next generation sequencing aren’t unpatentable as anticipated by or obvious over prior art, in an inter partes review by Integrated DNA Technologies Inc. The board that the challenged claims aren’t anticipated by or obvious over various combinations of prior art, including prior art that discloses an improved PCR method for walking in uncloned genomic DNA, preparation of next-generation sequencing ...